We are live on ! Find out more
Candriam SCA

Candriam SCA Portfolio holdings

AUM $22.5B Turnover 10.3%
1-Year Est. Return 50.38%
 

Candriam is a Luxembourg asset manager with sustainable investing at its core, run as a subsidiary of New York Life Investments, with Belgian bank Belfius holding a minority stake. It was previously Dexia Asset Management and took the Candriam name in 2014, short for "Conviction AND Responsibility In Asset Management", after New York Life's asset management arm acquired it. Its funds span bonds, stocks, absolute return strategies and asset allocation, and its portfolios exclude controversial weapons, thermal coal and tobacco. In 2021 it bought a majority stake in the European real estate manager Tristan Capital Partners.

This Fund
S&P 500
This Quarter Est. Return
+6.07%
1 Year Est. Return
+50.38%
3 Year Est. Return
+175.97%
5 Year Est. Return
+212.01%
10 Year Est. Return
+804.12%
AUM
$22.5B
AUM Growth
+$301M
Cap. Flow
-$416M
Cap. Flow %
-1.85%
Top 10 Hldgs %
34.05%
Holding
699
New
21
Increased
252
Reduced
270
Closed
51
Avg Time Held
6.2 years
Top 10 Avg Time Held
3.9 years
Top 20 Avg Time Held
3.4 years

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$98.2M
2
META icon
Meta Platforms (Facebook)
META
+$82.9M
3
NOW icon
ServiceNow
NOW
+$70.4M
4
INTC icon
Intel
INTC
+$58.4M
5
CRM icon
Salesforce
CRM
+$54.9M

Top Sells

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$102M
2
PANW icon
Palo Alto Networks
PANW
+$102M
3
ABBV icon
AbbVie
ABBV
+$68.9M
4
AMZN icon
Amazon
AMZN
+$57M
5
NVDA icon
NVIDIA
NVDA
+$54.1M

Sector Composition

Rank Sector Weight
1 Technology 41.06%
2 Healthcare 24.01%
3 Financials 9.02%
4 Communication Services 7.08%
5 Consumer Discretionary 6.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
TEVA icon
676
Teva Pharmaceutical Industries
TEVA
$49.7B
– –
-550,523
Closed -$18.6M –
THC icon
677
Tenet Healthcare
THC
$22.4B
– –
-16,439
Closed -$3.07M –
TYL icon
678
Tyler Technologies
TYL
$16.3B
– –
-5,890
Closed -$1.72M –
VNET icon
679
VNET Group
VNET
$730M
– –
-339,875
Closed -$2.73M –
WTRG icon
680
Essential Utilities
WTRG
$12.8B
– –
-150,268
Closed -$5.75M –
SION icon
681
Sionna Therapeutics
SION
$139M
– –
-233,208
Closed -$10.2M –

Similar funds

Candriam SCA's Q3 2026 Portfolio in Review

As of Q3 2026, Candriam SCA held 699 positions worth $22.5B, up 1.4% from $22.2B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Candriam SCA's Q3 2026 filing shows 21 new, 252 increased, 270 reduced and 51 closed positions. Its largest new stake was Zenas BioPharma: 654,833 shares worth $17.7M. The largest sale was Alphabet (Google) Class A, an estimated $102M.

By sector, the portfolio is most concentrated in Technology at 41% of assets, up from 38% a quarter earlier, followed by Healthcare and Financials.

  • Candriam SCA's largest Q3 2026 buy was Zenas BioPharma: 654,833 shares worth $17.7M.
  • Candriam SCA added most to Abbott in Q3 2026, an estimated $98.2M increase.
  • Candriam SCA's biggest Q3 2026 reduction was Alphabet (Google) Class A, cutting an estimated $102M.
  • Candriam SCA fully exited StoneX in Q3 2026, selling an estimated $46.1M.
  • Candriam SCA's ten largest holdings make up 34% of its $22.5B portfolio in Q3 2026.
  • Candriam SCA opened 21 new positions and closed 51 in Q3 2026.
  • Candriam SCA's portfolio value rose 1.4% quarter-over-quarter to $22.5B.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.